Novavax Can Still Find Growth Opportunities Abroad

InvestorPlace2021-12-01

Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

JayD
2021-12-01
JayD
Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?
- ngckkk:
  agree!
sfleong1
2021-12-01
sfleong1
Like n comment
- JayD:
  done
KW1
2021-12-01
KW1
Ok like

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1164737284?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-01 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164737284","market":"us","top_or_hot":-1,"title":"Novavax Can Still Find Growth Opportunities Abroad","media":"InvestorPlace","content":"<div>\n<p>Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for ...</p>\n\n<a href=\"https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Can Still Find Growth Opportunities Abroad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Can Still Find Growth Opportunities Abroad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 15:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for ...</p>\n\n<a href=\"https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/","article_id":"1164737284","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164737284","pubTimestamp":1638343312,"sourceInfo":null,"weMediaInfo":null,"summary":"NVAX stock has been wobbly in 2021, but next year could provide a breakout moment","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药仍能在国外找到增长机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for much of 2021 has been lackluster. Yet, Novavax’s progress shouldn’t only be measured in the U.S. Remember, Covid-19 is an international problem and vaccines can be commercialized in different regional markets.\nA challenge for Novavax has been getting its Covid-19 vaccine candidate approved, or at least considered, by regulators in these markets abroad.\nFortunately, as we’ll see, the company has demonstrated success in this endeavor. Hopefully, this will bring more investors into the bull camp, thereby boosting the price of NVAX stock.\nNVAX Stock at a Glance\nThere’s no such thing as a guaranteed floor in technical stock analysis. The only exception might be zero, as a stock can’t go any lower than that. Still, around $120 appears to be a pretty solid floor, or at least a support level, for NVAX stock. Indeed, the stock bounced off of that level in January, May and October of this year.\nThe biggest of those three bounces took place early in the year, when the Novavax share price hit a 52-week high of $331.68. This event demonstrated how high the stock is capable of going, though in theory there’s really no limit. Heading into late November, NVAX stock was trading at approximately $200.\nTechnicians might say that the stock is somewhere in the middle of its defined range. Watch closely for a breakout above $275, which could galvanize the buyers and perpetuate a long-term rally.\nMaking Strides in South Korea\nAgain, we must emphasize that the battle against Covid-19 is taking place on multiple regional fronts.\nFor instance, Novavax appears to be making progress towards regulatory approval in South Korea. Specifically, Novavax, along with South Korea biotechnology company SK Bioscience,submitted a Biologics License Application (BLA) for Novavax’ Covid-19 vaccine toSouth Korea’sMinistry of Food and Drug Safety (MFDS). Known as NVX-CoV2373, Novavax’s Covid-19 vaccine with a Matrix-M adjuvant is the first protein-based Covid-19 vaccine to be submitted for a BLA in South Korea.\nIt’s been a long-awaited event, as Novavax and SK Bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS back in April of this year.\nMoreover, full approval could be granted next, as this BLA submission to the MFDS represents the final review stage for authorization of NVX-CoV2373 in South Korea.\nStanley C. Erck, the president and CEO of Novavax, observed the broader implications of this BLA submission: “Today’s submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow,”Erck explained.\nAn Announcement in Europe\nMeanwhile, Novavax revealed that the European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for NVX-CoV2373. If everything goes as planned, Novavax’s Covid-19 vaccine will be marketed in the European Union under the brand name Nuvaxovid.\nThis CMA application is just one of many regulatory filings that Novavax has made.\nOther filings have been made in theUnited Kingdom, Australia, New Zealand and Canada. Plus, Novavax filed to get its Covid-19 vaccine candidate approved by the World Health Organization (WHO).\nYet, some stakeholders might consider the EMA application by itself to be particularly impactful for Novavax.\nWithout a doubt, securing a marketing authorization in Europe could open the door to significant revenue streams for Novavax.\nThe Takeaway\nOpportunities to combat the Covid-19 pandemic exist in multiple regions of the world. There’s no denying that Novavax isn’t the most successful Covid-19 vaccine developer in the U.S. I currently give NVAX stock a “B” in myPortfolio Grader.\nHowever, don’t dismiss the company’s progress abroad.\nInternational regulatory wins in the coming months would help Novavax advance its Covid-19 vaccine candidate, and thereby provide greater value to the shareholders.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":603058472,"gmtCreate":1638344118560,"gmtModify":1638344119035,"author":{"id":"3575345755723136","authorId":"3575345755723136","name":"JayD","avatar":"https://static.tigerbbs.com/351a615bb9b62fee1934015c7f6d857b","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575345755723136","authorIdStr":"3575345755723136"},"htmlText":"Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?","listText":"Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?","text":"Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603058472","repostId":1164737284,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6797359,"gmtCreate":1638346336170,"gmtModify":1638346336203,"authorId":3556014229499035,"author":{"id":3556014229499035,"idStr":"3556014229499035","authorId":3556014229499035,"name":"ngckkk","avatar":"https://static.tigerbbs.com/d1e114dfd4580625c8151f1dd0b330fc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603058472,"type":1,"supId":0,"prevId":0,"content":"agree!","text":"agree!","html":"agree!"}],"langContent":"CN"},{"id":603053213,"gmtCreate":1638343606505,"gmtModify":1638343607475,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603053213","repostId":1164737284,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6796997,"gmtCreate":1638344089432,"gmtModify":1638344089462,"authorId":3575345755723136,"author":{"id":3575345755723136,"idStr":"3575345755723136","authorId":3575345755723136,"name":"JayD","avatar":"https://static.tigerbbs.com/351a615bb9b62fee1934015c7f6d857b","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603053213,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":603059582,"gmtCreate":1638343481423,"gmtModify":1638343482023,"author":{"id":"3563714281601583","authorId":"3563714281601583","name":"KW1","avatar":"https://static.tigerbbs.com/094e3f8fd8b3de3da976515926ed1403","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3563714281601583","authorIdStr":"3563714281601583"},"htmlText":"Ok like","listText":"Ok like","text":"Ok like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603059582","repostId":1164737284,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":18,"commentSize":3,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164737284"}